South32 Limited (LON:S32) “Sell” Rating Kept by Analysts at Liberum Capital; The PT Given is GBX 90.00; Aerie Pharmaceuticals (AERI) Sentiment Is 1.73

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. The company has market cap of $2.06 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It currently has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

South32 Limited (LON:S32) had its stock rating noted as “Sell” by analysts at Liberum Capital. Liberum Capital currently has a GBX 90.00 price target on the 11.53 billion GBP market cap company or -55.53% downside potential. This was shown in a report on Thursday morning.

Ratings analysis reveals 100% of Aerie Pharma’s analysts are positive. Out of 8 Wall Street analysts rating Aerie Pharma, 8 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $50.0 while the high is $69.0. The stock’s average target of $57 is 8.47% above today’s ($52.55) share price. AERI was included in 8 notes of analysts from September 14, 2016. RBC Capital Markets maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating on Thursday, September 15. RBC Capital Markets has “Outperform” rating and $55.0 target. The firm has “Buy” rating by Aegis Capital given on Tuesday, November 1. Cantor Fitzgerald maintained the stock with “Buy” rating in Thursday, September 15 report. Needham maintained the shares of AERI in report on Thursday, September 15 with “Buy” rating. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by Roth Capital on Friday, February 17. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given on Thursday, September 15 by Stifel Nicolaus. The rating was initiated by Raymond James on Wednesday, September 14 with “Strong Buy”. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, September 20.

The stock decreased 2.95% or $1.6 during the last trading session, reaching $52.55. About 304,325 shares traded. Aerie Pharmaceuticals, Inc. (AERI) has risen 180.20% since February 15, 2017 and is uptrending. It has outperformed by 163.50% the S&P500.

Foresite Capital Management Ii Llc holds 32.95% of its portfolio in Aerie Pharmaceuticals, Inc. for 1.67 million shares. Dafna Capital Management Llc owns 116,770 shares or 3.52% of their US portfolio. Moreover, Senzar Asset Management Llc has 2.74% invested in the company for 231,200 shares. The New York-based Iguana Healthcare Management Llc has invested 2.71% in the stock. Sectoral Asset Management Inc, a Quebec – Canada-based fund reported 373,396 shares.

Analysts await Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) to report earnings on March, 6. They expect $-1.44 earnings per share, down 65.52% or $0.57 from last year’s $-0.87 per share. After $-0.89 actual earnings per share reported by Aerie Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 61.80% negative EPS growth.

Among 12 analysts covering South32 Limited Ord Npv Di Wi (LON:S32), 4 have Buy rating, 2 Sell and 6 Hold. Therefore 33% are positive. South32 Limited Ord Npv Di Wi has GBX 265 highest and GBX 47 lowest target. GBX 179.33’s average target is -10.34% below currents GBX 200 stock price. South32 Limited Ord Npv Di Wi had 209 analyst reports since July 23, 2015 according to SRatingsIntel. The stock of South32 Limited (LON:S32) earned “Underperform” rating by Macquarie Research on Wednesday, August 24. The stock of South32 Limited (LON:S32) earned “Buy” rating by Jefferies on Thursday, November 10. Jefferies maintained South32 Limited (LON:S32) rating on Tuesday, April 18. Jefferies has “Buy” rating and GBX 225 target. BNP Paribas maintained South32 Limited (LON:S32) rating on Tuesday, August 30. BNP Paribas has “Outperform” rating and GBX 130 target. The stock has “Overweight” rating by Barclays Capital on Monday, January 9. The company was maintained on Thursday, May 11 by Citigroup. The firm has “Equal Weight” rating by Barclays Capital given on Friday, August 26. On Thursday, December 1 the stock rating was maintained by BNP Paribas with “Neutral”. The company was maintained on Wednesday, June 29 by BNP Paribas. As per Thursday, May 5, the company rating was maintained by Barclays Capital.

The stock decreased 5.84% or GBX 12.4 during the last trading session, reaching GBX 200. About 1.75M shares traded. South32 Limited (LON:S32) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

South32 Limited operates as a diversified metals and mining firm primarily in Australia, Southern Africa, and South America. The company has market cap of 11.53 billion GBP. The firm has a portfolio of assets producing alumina, aluminum, bauxite, energy and metallurgical coal, manganese ore and alloy, ferronickel, silver, lead, and zinc. It has a 8.73 P/E ratio. It also exports its products.